OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

Quick facts about Optune

  • Long-term data 5-year survival results in newly diagnosed GBM
  • Experience >15,000 patients with GBM started Optune®
  • Availability 1,300+ certified medical centers prescribing Optune® for GBM
  • Long-term data 5-year survival results in newly diagnosed GBM
  • Experience >15,000 patients with GBM started Optune®
  • Availability 1,300+ certified medical centers prescribing Optune® for GBM
  • Optune is a noninvasive, portable device that is classified as durable medical equipment (DME).

    Optune® device components including transducer arrays, batteries and charger, easy-access sleeve bag, convertible 5-in-1 bag, electric field generator, plug-in power supply, connection cable and box

    Optune® device components including transducer arrays, batteries and charger, easy-access sleeve bag, convertible 5-in-1 bag, electric field generator, plug-in power supply, connection cable and box

  • Optune provides continuous action against disease progression by delivering Tumor Treating Fields (TTFields) to selectively disrupt mitosis in dividing cancer cells.

    • Watch how TTFields can disrupt cancer cell division. This video shows the mechanism of action of TTFields
  • Transducer arrays are applied to the shaved scalp and must be changed at least 2 times per week (every 4 days, at most)

    • Arrays should always have good scalp contact
    • Note: Avoid activities that may result in the device or transducer arrays becoming wet. Getting the device wet may cause it damage

    Recommended usage goal for Optune is 18+ hrs/day, which gives patients flexibility to decide which times of day are best for use4

    The recommended daily usage for Optune® is 18+ hours a day

    Patients can benefit most from wearing Optune for the recommended time

    • In the phase 3 pivotal trial, 75% of patients used Optune 18 or more hours a day during the first 3 months of treatment5
      • 50% daily use was the threshold for significant survival benefit over TMZ alone
      • 86% of patients received a survival benefit from Optune, because they used it more than half the time (n=388/450)

    Adjusting to Optune

    • This brief video shows Optune users and caregivers providing their perspectives on starting to use Optune

Simple steps to start patients on Optune

Novocure® has identified a 4-step process that may help your patients with GBM start Optune and achieve their treatment goals.

Get details about practice support available

GBM, glioblastoma; TMZ, temozolomide.

References: 1. Optune. Instructions for Use for Glioblastoma. Novocure; 2019. 2. China NMPA approves Optune® for the treatment of newly diagnosed and recurrent glioblastoma [press release]. St. Helier, Jersey and Shanghai: Business Wire; May 13, 2020. Accessed December 7, 2020. 3. Novocure Data on File OPT-115.3. 4. Optune. Patient Information and Operation Manual. Novocure; 2019. 5. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).